Foa, Robin
 Distribuzione geografica
Continente #
NA - Nord America 1.612
AS - Asia 1.004
EU - Europa 783
SA - Sud America 268
AF - Africa 25
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 3.700
Nazione #
US - Stati Uniti d'America 1.582
SG - Singapore 479
CN - Cina 247
BR - Brasile 222
SE - Svezia 222
IT - Italia 150
DE - Germania 97
IN - India 75
IE - Irlanda 65
VN - Vietnam 65
PL - Polonia 62
FR - Francia 61
GB - Regno Unito 38
ID - Indonesia 38
RU - Federazione Russa 25
AR - Argentina 24
MX - Messico 14
TR - Turchia 14
AT - Austria 13
FI - Finlandia 13
KR - Corea 13
UA - Ucraina 12
CA - Canada 11
HK - Hong Kong 11
JP - Giappone 9
BD - Bangladesh 8
IQ - Iraq 7
ZA - Sudafrica 7
AU - Australia 5
EG - Egitto 5
MA - Marocco 5
PK - Pakistan 5
CH - Svizzera 4
KZ - Kazakistan 4
LT - Lituania 4
PY - Paraguay 4
VE - Venezuela 4
AZ - Azerbaigian 3
PE - Perù 3
SA - Arabia Saudita 3
UY - Uruguay 3
UZ - Uzbekistan 3
BE - Belgio 2
BO - Bolivia 2
CI - Costa d'Avorio 2
CL - Cile 2
CO - Colombia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EC - Ecuador 2
IL - Israele 2
IR - Iran 2
NL - Olanda 2
NP - Nepal 2
RO - Romania 2
TT - Trinidad e Tobago 2
AL - Albania 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DO - Repubblica Dominicana 1
ES - Italia 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
LI - Liechtenstein 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
MY - Malesia 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 3.700
Città #
Singapore 222
Chandler 186
Ashburn 101
New York 60
Beijing 57
Dublin 57
Warsaw 56
Dallas 49
Dearborn 44
Hyderabad 41
Florence 38
Hefei 37
Jakarta 37
Los Angeles 37
Princeton 27
Frankfurt am Main 26
San Mateo 24
Wilmington 23
Ho Chi Minh City 22
São Paulo 22
Milan 21
Redwood City 21
Nanjing 18
Albany 16
Minneapolis 16
Boston 14
Nanchang 14
Chicago 13
Houston 13
Moscow 13
Pune 13
Seoul 13
Hanoi 12
Kunming 12
Düsseldorf 11
Hong Kong 11
Lauterbourg 11
Munich 10
Norwalk 10
London 9
Marseille 9
Belo Horizonte 8
Izmir 8
Nuremberg 8
Tokyo 8
Cattolica 7
Fairfield 7
Helsinki 7
Kent 7
Seattle 7
Atlanta 6
Garden City 6
Jacksonville 6
Rio de Janeiro 6
Rome 6
Bologna 5
Brooklyn 5
Buenos Aires 5
Changsha 5
Johannesburg 5
Tianjin 5
Wroclaw 5
Benalla 4
Brasília 4
Curitiba 4
Engelhard 4
Genoa 4
Goiânia 4
Haiphong 4
Orem 4
Poplar 4
Portsmouth 4
Santa Clara 4
Shenyang 4
The Dalles 4
Vicopisano 4
Vienna 4
Washington 4
Ankara 3
Baghdad 3
Baku 3
Bắc Giang 3
Cairo 3
Catanduva 3
Cleveland 3
Columbus 3
Falls Church 3
Fremont 3
Guarulhos 3
Juneau 3
Lahore 3
Manchester 3
Marília 3
Mirassol 3
Montevideo 3
Mountain View 3
Padova 3
Pelotas 3
Phoenix 3
Porto Alegre 3
Totale 1.708
Nome #
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 641
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia 157
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 132
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 132
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 129
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors. A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (Gitmo) 122
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphoma 105
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 105
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study 103
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 102
Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. 93
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 93
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 93
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 92
Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia 89
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 88
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 81
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 78
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 77
Anti-HLA donor-specific antibodies in allogeneic stem cell transplantation: management and desensitization protocol 76
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 76
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study 75
Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “Real-World” study 74
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 74
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 74
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 72
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 72
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 72
A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia 71
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab 70
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 69
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemia 68
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study 66
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment 65
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases 63
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study 54
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 41
Totale 3.744
Categoria #
all - tutte 16.586
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.586


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202139 0 0 0 0 0 9 8 1 5 5 7 4
2021/2022279 8 3 47 35 36 6 2 31 9 9 60 33
2022/2023489 64 73 32 58 37 67 14 31 65 7 31 10
2023/2024866 20 78 29 540 20 97 8 10 2 10 15 37
2024/2025724 24 16 47 23 49 35 22 32 93 134 157 92
2025/2026971 268 55 142 207 270 29 0 0 0 0 0 0
Totale 3.744